Back to results
US 12,606,614 B2Granted
Human FcRn-binding modified antibodies and methods of use
AssigneeHoffmann-La Roche Inc.
InventorsGuido Hartmann, Joerg Regula, Matthias Rueth, Wolfgang Schaefer, Tilman Schlothauer
Life of this patent
Estimating the term…
Abstract
Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.
Claims7
An antibody, comprising a first Fc-region polypeptide and a second Fc-region polypeptide, wherein the first and the second Fc-region polypeptide are both of human IgG1 of SEQ ID NO:
- 60 or human IgG4 subclass and comprise one or two of the mutations selected from the group H310A, H433A, and Y436A in the first Fc-region polypeptide and one or two of the mutations selected from the group consisting of the mutations H310A, H433A, and Y436A in the second Fc-region polypeptide so that all of the mutations in the first and the second Fc-region polypeptide when taken together result in that the mutations H310A, H433A, and Y436A are comprised in the Fc-region, wherein the numbering is according to the EU numbering of Kabat.
Dependencies are inferred from the claim text.